Dual Modality Treatment Solution for Dermatologists to be Featured at ASMS Fundamentals of Mohs Surgery Annual Meeting
Radiant™ Aura is a painless, non-surgical office-based radiation therapy treatment option for patients with non-melanoma skin cancers (NMSC) and keloid scarring
Xstrahl, a global leader in the delivery of superficial radiation therapy devices and preclinical radiation research systems, will feature Radiant™ Aura at the American Society for Mohs Surgery (ASMS) Fundamentals of Mohs Surgery Annual Meeting, November 14-17, 2024 at the Royal Sonesta Galleria, Houston, TX.
Radiant Aura is a low-dose, X-ray based, dual modality radiation therapy for treating non-melanoma skin cancers (NMSC) and keloid scarring. It is the only dual modality system that offers both non-invasive electronic brachytherapy (eBt) and superficial radiation therapy (SRT) for NMSC and keloid scarring.
“We’re pleased to feature Radiant Aura at this year’s ASMS Fundamentals of Moh’s Surgery Annual Meeting in Houston,” said Adrian Treverton, CEO of Xstrahl. “Radiant Aura is a painless non-surgical skin cancer treatment alternative available to support the delivery of office-based radiation therapy for patients with NMSC when surgery is not possible, contraindicated, or simply not preferred due to cosmetic concerns.”
Visit Xstrahl at the ASMS Fundamentals of Mohs Surgery Annual Meeting at the Royal Sonesta Galleria, Houston, TX, November 14-17, 2024.
To be placed on the VIP List for private events at the conference, please email brettshoemake@xstrahl.com.
To learn more about Radiant Aura, visit radiant-therapy.com
To learn more about all Xstrahl clinical and research systems, visit www.xstrahl.com
About Xstrahl
Xstrahl is a medical technology company that designs radiation delivery devices to support clinical teams and cancer researchers. For more than 25 years, Xstrahl has been shaping the development of superficial and orthovoltage radiation therapy and advancing preclinical radiation research. Xstrahl systems are in operation at more than 700 treatment and research facilities worldwide.
